Orientation Agnosia: Clinical and Anatomical Study (AGNORIENT)

September 1, 2014 updated by: University Hospital, Rouen

Orientation Agnosia: Neuropsychological Evaluation, Associated Symptoms, Clinical and Anatomical Correlations

The area of the brain responsible of visuospatial processing data and more specifically the orientation of an object or image is located in parietal lobe, especially on the right side. A dysfunction of this region would result in a disorder of recognition of the orientation of objects and images that the investigators call orientation agnosia. Several isolated cases are reported in the literature but to the investigators knowledge deficit has never been systematically searched, or put into perspective compared to other neuropsychological deficits. Moreover, the precise location of the lesion responsible for such a disorder remains uncertain. The objectives of this study are (1) detect the existence of orientation agnosia in case of right parietal lesion, and (2) to improve the understanding of such a deficit allowing better management of this disorder.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Idem

Study Type

Interventional

Enrollment (Actual)

34

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
    • Haute-Normandie
      • Rouen, Haute-Normandie, France, 76031
        • CHU de rouen - Hôpitaux de Rouen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • age between 18 and 80 years
  • french language
  • right parietal lesion on cerebral imaging (CT-scan is sufficient), including stroke,arterial malformation, isolated tumoral lesion
  • informed consent

Exclusion Criteria:

  • previous neurological history except non complicated migraine and stabilized epilepsia without seizure since 5 years
  • previous psychiatric history except depression without hospitalization > one week or anxiety with maximum one anxiolytic treatment
  • drug or alcohol abuse
  • severe cranial traumatism
  • other severe chronic pathology
  • psychotropic medication other than a hypnotic or an anxiolytic at low doses without dose modification for at least one month
  • visual impairment
  • motor or sensory deficit sufficient to render impossible neuropsychological tests
  • patient without judicial or administrative liberty
  • measure of legal protection or no capable to express their consent
  • pregnancy or breastfeeding

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: patient with right parietal lesions
Behavioral: Neuropsychological testing
Experimental test about orientation agnosia and standard neuropsychological tests.
Other: MRI
Cerebral MRI
Active Comparator: patient with left parietal lesions
Behavioral: Neuropsychological testing
Experimental test about orientation agnosia and standard neuropsychological tests.
Other: MRI
Cerebral MRI

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
orientation agnosia evaluation
Time Frame: 1 week to 6 months (average)
orientation agnosia test
1 week to 6 months (average)

Secondary Outcome Measures

Outcome Measure
Time Frame
associated clinical symptoms especially apraxia
Time Frame: 1 week to 6 months (average)
1 week to 6 months (average)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Rouen

Investigators

  • Principal Investigator: Olivier MARTINAUD, Doctor, Service de neurologie et centre mémoire de ressources et recherche

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2010

Primary Completion (Actual)

December 1, 2013

Study Completion (Actual)

December 1, 2013

Study Registration Dates

First Submitted

August 23, 2010

First Submitted That Met QC Criteria

February 23, 2011

First Posted (Estimate)

February 25, 2011

Study Record Updates

Last Update Posted (Estimate)

September 3, 2014

Last Update Submitted That Met QC Criteria

September 1, 2014

Last Verified

September 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2009/126/HP
  • number ID RCB 2009-A01005-52 (Other Identifier: Afssaps)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebrovascular Disorders

Clinical Trials on Neuropsychological testing

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe